Welcome to PsorVal.net | DermaSolve.net !


Your Source for Psor-Val | DermaSolve | Absorbase


 Serving Treatment Solutions for Psoriasis, Eczema, Dry Skin 


Providing News, Views, Tips and Tricks

along with great products for that   "Healthy You" 


Looking for Psor-Val Spray? Click here 


Now Shipping Psor-Val Spray World Wide

 International Clients - Click "We Ship Worldwide!"

MedWorm: Psoriasis

Immunohistochemical Expression of MCM2 in Nonmelanoma Epithelial Skin Cancers (Sat, 22 Nov 2014)
Abstract:Cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) represent 45.5% and 37.02%, respectively, of total malignant skin cancer according to the latest registry of Egyptian National Cancer Institute. Minichromosome maintenance (MCM) proteins are essential replication initiation factors. The current study examined the immunohistochemical expression of MCM2 in normal skin (10 cases), some proliferative skin lesions (6 psoriasis, 2 keratoacanthoma, and 2 seborrheic keratosis), and nonmelanoma epithelial skin cancers (20 BCC and 21 SCC). MCM2 was expressed in basal layer of normal epidermis and upregulated in proliferative skin lesions and nonmelanoma epithelial skin cancers without significant differences between the latter groups (P > 0.05). Mean and median values of... MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space...
>> read more

CHMP Backs Secukinumab, Apremilast for PsoriasisCHMP Backs Secukinumab, Apremilast for Psoriasis (Fri, 21 Nov 2014)
The European Medicines Agency committee has recommended secukinumab and apremilast for moderate to severe plaque psoriasis and apremilast for active psoriatic arthritis. International Approvals (Source: Medscape Medical News Headlines)
>> read more

Celgene receives positive CHMP opinion for OTEZLA® (apremilast) (Fri, 21 Nov 2014)
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications. (Source: Pharmacy Europe)
>> read more

Ten Years On: The Impact of Biologics on the Practice of Dermatology (Fri, 21 Nov 2014)
This review delivers a commentary on the first decade of biologics’ use in psoriasis and provides a glimpse of the pipeline of therapies currently in development for psoriasis that will enhance the therapeutic armamentarium available to the dermatologist. In addition, the authors revisit the rationale for the development of biological therapies, inventory the available therapies of today, and retrospectively assess their impact on the dermatology practice as it relates to the management of patients with psoriasis. (Source: Dermatologic Clinics)
>> read more

Psoriatic Arthritis for the Dermatologist (Fri, 21 Nov 2014)
Psoriatic arthritis (PsA) is a chronic, progressive, inflammatory spondyloarthropathy that affects approximately one-third of patients with all types of psoriasis. Dermatologists are in a unique position to recognize early symptoms of PsA, initiate appropriate therapy, and prevent development of further disability. The course of PsA can be modulated by immunosuppressive therapy; patients with moderate-to-severe disease require aggressive management with medications proven to halt disease progression. It is essential for the dermatologist to understand the safety, tolerability, efficacy, cost, and potential to halt disease progression with available medications for this relatively common and potentially disabling disease. (Source: Dermatologic Clinics)
>> read more

Pharmacogenomics and the Resulting Impact on Psoriasis Therapies (Fri, 21 Nov 2014)
Psoriasis is a model disease for the development of pharmacogenomic markers of treatment response, with ready access to diseased tissue and objective validated outcome measures. With the application of state-of-the-art technologies and investment in careful experimental design, the goal of stratified medicine in psoriasis may be possible. Current pharmacogenomic studies in psoriasis show excellence in many areas, including the investigation of a broad range of psoriasis therapies. To facilitate the advent of stratified medicine in psoriasis, uniformity of study design is required, with high quality, consistent phenotyping strategies for participants; definitions of outcome; and the publication of reproducible methodologies. (Source: Dermatologic Clinics) MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space...
>> read more

Psoriasis: The Future (Fri, 21 Nov 2014)
The umbrella term psoriasis is now understood to incorporate several distinct phenotypes or endotypes along the disease spectrum that in turn will dictate different therapies. A stratified medicine approach to psoriasis using this clinical information coupled with pharmacogenomic and immunologic data will become more widely acceptable in the future. Comorbidities associated with psoriasis, such as diabetes, depression, and Crohn disease, and the debate about the interdependence of psoriasis and cardiovascular disease will also dictate future research and holistic and management plans for this complex disease. (Source: Dermatologic Clinics)
>> read more

Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice (Fri, 21 Nov 2014)
Psoriasis is a complex disease. Dermatologists have not documented psoriasis severity, except in clinical trials; doing so requires tools for assessing psoriasis and an understanding of what changes in those assessments mean in terms of outcome. Two psoriasis assessment tools have dominated: The Psoriasis Area and Severity Index and the Dermatology Life Quality Index. There are advantages and disadvantages to each. Newer instruments may not be more suitable for documenting psoriasis. There may be benefits in terms of patient ownership of disease management from using self-assessment tools for documenting severity, for example, the Self-assessment version of the Simplified Psoriasis Index. (Source: Dermatologic Clinics)
>> read more

An Update on Topical Therapies for Mild-Moderate Psoriasis (Fri, 21 Nov 2014)
Topical therapies are the mainstream treatment of psoriasis because most patients have mild disease. First-line treatments are vitamin D derivatives and corticosteroids. These treatments are usually given in combination schedules. For topical treatments the selection of the most appropriate vehicle is of major importance, thus improving adherence to the treatment, which frequently is impaired by the complexities of topical therapeutic choices. Evidence for efficacy and safety of topical treatments is readily available for vitamin D treatments and short-term treatment with corticosteroids. However, the scientific evidence for longer-term treatments is limited. Multiple new small molecules are in various stages of development and are reviewed. (Source: Dermatologic Clinics)
>> read more

Phototherapy and Photochemotherapy for Psoriasis (Fri, 21 Nov 2014)
Phototherapy is a first-line option for the treatment of moderate to severe psoriasis. Systematic reviews indicate near comparable efficacy of the different forms of phototherapy. Localized phototherapy can be an adjunctive treatment of recalcitrant plaques during systemic treatment of psoriasis. More than 200 psoralen–UV-A therapy treatment sessions is associated with an increased risk of keratinocytic cancers, whereas no increased risk has been demonstrated for narrow-band UV-B therapy. The mechanism of action of phototherapy in psoriasis is via inhibition of keratinocyte proliferation; induction of apoptosis in keratinocytes, dendritic, and T cells; and inhibition of Th1 and Th17 pathways, but activation of Th2. (Source: Dermatologic Clinics)
>> read more


Scan our QR Code to your Smart Phone / iPhone Users download QR Reader from Tap Media http://www.TapMedia.co.uk 

Real Time Web Analytics

International Clients, After adding products to Cart - Refresh your browser if you do not see the "International Checkout" Button

Psor-Val Zinc Spray, DermaSolve Psoriasis Care Products and

Absorbase Cream for Moisturizing Skin Care.


Treatment Solutions and Products for Psoriasis, Eczema, Dry Skin. Natural Care for that Healthy You!